TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32432489

Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO) as monotherapy for R/R AML
Number of subjects: 331
Study: 32432839

Group type: EXPERIMENTAL
Intervention: MitraClip
Number of subjects: 86
Study: 32433094

Group type: EXPERIMENTAL
Intervention: iStent inject devices
Number of subjects: 42
Study: 32433237

Group type: EXPERIMENTAL
Intervention: Islet cell grafts cultured for ≥96 hours
Number of subjects: 40
Study: 32433600

Group type: EXPERIMENTAL
Intervention: Neoadjuvant modified FOLFIRINOX (mFOLFIRINOX)
Number of subjects: 44
Study: 32433647

Group type: EXPERIMENTAL
Intervention: Metabolite changes in fasting plasma samples among women with incident T2D
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Baseline metabolic profile
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Longitudinal analysis of metabolic changes
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Pathway analysis
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Longitudinal analyses
Number of subjects: 173
Study: 32433728

Group type: EXPERIMENTAL
Intervention: Homozygous hemoglobin E variant (Hb EE)
Number of subjects: 515

Group type: COMPARATOR
Intervention: Normal hemoglobin AA genotype
Number of subjects: 515
Study: 32433768

Group type: EXPERIMENTAL
Intervention: Dreem headband (DH)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Polysomnography (PSG)
Number of subjects: 25
Study: 32433821

Group type: EXPERIMENTAL
Intervention: Amplatzer Piccolo Occluder
Number of subjects: 200
Study: 32433894

Group type: EXPERIMENTAL
Intervention: Inactive patients
Number of subjects: 1946

Group type: EXPERIMENTAL
Intervention: Highly active patients
Number of subjects: 1946

Group type: COMPARATOR
Intervention: Active patients
Number of subjects: 1946
Study: 32433993

Group type: EXPERIMENTAL
Intervention: WMFT-RPSS
Number of subjects: 29
Study: 32434278

Group type: EXPERIMENTAL
Intervention: Vamorolone (VBP15)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 32434935

Group type: EXPERIMENTAL
Intervention: Dabigatran initiation within 3 months after the ischaemic stroke
Number of subjects: 1489

Group type: EXPERIMENTAL
Intervention: Dabigatran initiation
Number of subjects: 1489
Study: 32435020

Group type: EXPERIMENTAL
Intervention: C1 inhibitor (C1-INH) 1000U administered biweekly via intravenous infusion
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: C1 inhibitor (C1-INH)
Number of subjects: 8
Study: 32435762

Group type: EXPERIMENTAL
Intervention: Online education (OLE)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Interprofessional education (IPE)
Number of subjects: 20
Study: 32436060

Group type: EXPERIMENTAL
Intervention: PF-06840003 (500 mg BID)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: PF-06840003 (various doses)
Number of subjects: 17
Study: 32436180

Group type: EXPERIMENTAL
Intervention: F-18 fluorocholine PET/CT
Number of subjects: 30

Group type: COMPARATOR
Intervention: Tc-99m sestamibi
Number of subjects: 30

Group type: COMPARATOR
Intervention: Neck ultrasound
Number of subjects: 30
Study: 32436335

Group type: EXPERIMENTAL
Intervention: Sofosbuvir (400 mg/d) plus Daclatasvir with or without Ribavirin (1-1.2 g/d) for 12 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sofosbuvir (400 mg/d) plus Daclatasvir with or without Ribavirin (1-1.2 g/d) for 24 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ribavirin addition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sofosbuvir/Daclatasvir with or without Ribavirin
Number of subjects: 0
Study: 32436724

Group type: EXPERIMENTAL
Intervention: Brief interval exercise training (IET) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 32436923

Group type: EXPERIMENTAL
Intervention: Implementation of a risk-management framework for incorporating stromal tumor-infiltrating lymphocytes (sTILs) in clinical trials.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: sTILs as an integral biomarker in a single-center phase II immunotherapy trial (TONIC trial, NCT02499367).
Number of subjects: 0
Study: 32437328

Group type: EXPERIMENTAL
Intervention: Tailored mHealth support intervention for physical activity (PA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 60
Study: 32437423

Group type: EXPERIMENTAL
Intervention: Optimized nutrition protocol (Group 2)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Standard nutrition protocol (Group 1)
Number of subjects: 158
Study: 32437557

Group type: EXPERIMENTAL
Intervention: dihydroartemisinin/piperaquine (4 mg/kg/day for 3 days)
Number of subjects: 60

Group type: COMPARATOR
Intervention: artesunate monotherapy followed by dihydroartemisinin/piperaquine (4 mg/kg/day for 3 days)
Number of subjects: 60
Study: 32437664

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg flat dose IV) + Trastuzumab (8 mg/kg loading dose IV) + chemotherapy
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Pembrolizumab + Trastuzumab + chemotherapy
Number of subjects: 37
Study: 32437738

Group type: EXPERIMENTAL
Intervention: Midostaurin treatment
Number of subjects: 116
Study: 32438272

Group type: EXPERIMENTAL
Intervention: SC-002
Number of subjects: 35
Study: 32438338

Group type: EXPERIMENTAL
Intervention: mHealth intervention including health reminders and psychoeducational messaging plus clinical standard of care reminders.
Number of subjects: 54

Group type: COMPARATOR
Intervention: Standard of care reminders only (mailed appointments and automated telephone calls).
Number of subjects: 54
Study: 32438452

Group type: EXPERIMENTAL
Intervention: Eliglustat therapy
Number of subjects: 231
Study: 32438917

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced mammography (CEM)
Number of subjects: 47
Study: 32439432

Group type: EXPERIMENTAL
Intervention: Low-dose capsaicin (0.01 mM) nasal spray
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment for idiopathic rhinitis
Number of subjects: 0
Study: 32439653

Group type: EXPERIMENTAL
Intervention: Bempegaldesleukin (NKTR-214) plus Nivolumab
Number of subjects: 38
Study: 32439700

Group type: EXPERIMENTAL
Intervention: iNeo-Vac-P01 (neoantigen vaccine)
Number of subjects: 22
Study: 32439737

Group type: EXPERIMENTAL
Intervention: HbA1c assessment for diabetes mellitus (DM) and prediabetes (pre-DM) diagnosis
Number of subjects: 992

Group type: EXPERIMENTAL
Intervention: HbA1c assessment in patients aged 50-59 years
Number of subjects: 992

Group type: EXPERIMENTAL
Intervention: HbA1c assessment in patients aged ≥60 years
Number of subjects: 992

Group type: EXPERIMENTAL
Intervention: HbA1c assessment in overweight patients
Number of subjects: 992

Group type: EXPERIMENTAL
Intervention: HbA1c assessment in obese patients
Number of subjects: 992

Group type: COMPARATOR
Intervention: HbA1c assessment in patients aged 18-29 years
Number of subjects: 992

Group type: COMPARATOR
Intervention: HbA1c assessment in normal-weight patients
Number of subjects: 992

Group type: EXPERIMENTAL
Intervention: Logistic regression analysis for predictors of DM
Number of subjects: 992
Study: 32440228

Group type: EXPERIMENTAL
Intervention: Ethinylestradiol 20 μg/Drospirenone 3 mg
Number of subjects: 186

Group type: COMPARATOR
Intervention: Post-treatment SF-36v2 scores
Number of subjects: 186
Study: 32440613

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 32440638

Group type: EXPERIMENTAL
Intervention: Combination antiretroviral therapy (cART)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anemia during pregnancy
Number of subjects: 0
Study: 32440790

Group type: EXPERIMENTAL
Intervention: Serum ferritin and fever
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Soluble CD25
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Non-malignancy-associated HLH
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Malignancy-associated HLH
Number of subjects: 73
Study: 32441114

Group type: EXPERIMENTAL
Intervention: Adjudicated major adverse cardiovascular events
Number of subjects: 16485

Group type: EXPERIMENTAL
Intervention: Non-serious adverse events
Number of subjects: 16485

Group type: EXPERIMENTAL
Intervention: Medical Dictionary for Regulatory Activities terms
Number of subjects: 16485

Group type: EXPERIMENTAL
Intervention: Adjudicated deaths
Number of subjects: 16485

Group type: EXPERIMENTAL
Intervention: Site assessment of cardiovascular death
Number of subjects: 16485
Study: 32441582

Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 1120
Study: 32441892

Group type: EXPERIMENTAL
Intervention: Low-dose apatinib (500 mg or 250 mg per day)
Number of subjects: 747
Study: 32442144

Group type: EXPERIMENTAL
Intervention: InCharge Health app
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: HU Toolbox app
Number of subjects: 8
Study: 32442254

Group type: EXPERIMENTAL
Intervention: Isolated CABG
Number of subjects: 2397
Study: 32442603

Group type: EXPERIMENTAL
Intervention: Large-bore sheaths (>21F outer diameter)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Small-bore sheaths (≤21F outer diameter)
Number of subjects: 360
Study: 32442637

Group type: EXPERIMENTAL
Intervention: Automated segmentation and surface extraction pipeline for T1-weighted neuroimaging data
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparator software solutions
Number of subjects: 0
Study: 32442638

Group type: EXPERIMENTAL
Intervention: Increased network integration in older adults during high difficulty working memory tasks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Decreased network integration in younger adults during high difficulty working memory tasks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher WM capacity in older adults
Number of subjects: 0
Study: 32442785

Group type: EXPERIMENTAL
Intervention: Oral rigosertib (140 mg twice daily, 280 mg twice daily, or 840 mg/day [560 mg morning/280 mg evening]) for 3 weeks of a 4-week cycle
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Parenteral azacitidine (75 mg/m2)
Number of subjects: 18
Study: 32443037

Group type: EXPERIMENTAL
Intervention: GERD group
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: GERD with erosive esophagitis
Number of subjects: 219

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 219
Study: 32443041

Group type: EXPERIMENTAL
Intervention: Oral Glucose Tolerance Test (OGTT) performed between 2.5 and 3.5 months of age.
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Abnormal OGTT defined as early hyperglycaemia (>1.8 g/L until 30 minutes; >1.7 g/L between 30 minutes and 2 hours; and >1.4 g/L between 2 and 3 hours) and/or late hypoglycaemia (<0.6 g/L after 2 hours).
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Screening for potential dumping syndrome (DS) using OGTT around 3 months of age.
Number of subjects: 38
Study: 32443148

Group type: EXPERIMENTAL
Intervention: Modern ART
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Immunologic interventions
Number of subjects: 22
Study: 32444192

Group type: EXPERIMENTAL
Intervention: Direct venous inoculation (DVI) of PfSPZ Vaccine (0.5 mL)
Number of subjects: 511

Group type: EXPERIMENTAL
Intervention: Direct venous inoculation (DVI) of PfSPZ Vaccine
Number of subjects: 511
Study: 32444241

Group type: EXPERIMENTAL
Intervention: Daily multivitamin/micronutrients supplement
Number of subjects: 0
Study: 32444411

Group type: EXPERIMENTAL
Intervention: Oral iron supplementation with ferric maltol
Number of subjects: 0
Study: 32444417

Group type: EXPERIMENTAL
Intervention: Cediranib plus Olaparib (Olaparib 300 mg twice daily + Cediranib 20 mg once daily)
Number of subjects: 34
Study: 32444431

Group type: EXPERIMENTAL
Intervention: Higher intake of vitamin K2
Number of subjects: 2987

Group type: EXPERIMENTAL
Intervention: Vitamin K1 intake
Number of subjects: 2987
Study: 32444455

Group type: EXPERIMENTAL
Intervention: Statin use
Number of subjects: 606

Group type: COMPARATOR
Intervention: No statin use (Control)
Number of subjects: 606
Study: 32444557

Group type: EXPERIMENTAL
Intervention: Temperament Harm Avoidance
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Character Self-Directedness
Number of subjects: 333
Study: 32444996

Group type: EXPERIMENTAL
Intervention: Protein intake, source and distribution
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Fruit and vegetable intakes
Number of subjects: 130
Study: 32445415

Group type: EXPERIMENTAL
Intervention: Propofol sedation for patients with anxiety symptoms
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propofol sedation for patients with depression symptoms
Number of subjects: 0
Study: 32445848

Group type: EXPERIMENTAL
Intervention: Pain Catastrophizing Scale scores
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Average pain intensity
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Average pain intensity in remitting trajectory
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Physical function
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Preoperative average pain intensity scores
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Preoperative physical function scores
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Prolonged hospitalization, smoking, and preoperative opioid prescriptions
Number of subjects: 348
Study: 32446108

Group type: EXPERIMENTAL
Intervention: Prolonged Exposure + Placebo (PE + PLB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sertraline + Prolonged Exposure (SERT + PE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sertraline + Enhanced Medication Management (SERT + EMM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combat controls
Number of subjects: 0
Study: 32446407

Group type: EXPERIMENTAL
Intervention: Regulatory cell-based medicinal products (CBMPs) in CTG trials
Number of subjects: 104

Group type: COMPARATOR
Intervention: Standard-of-care immunosuppression in RGT (basiliximab, tapered steroids, mycophenolate mofetil, tacrolimus)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Combined adverse event data from CTG trials
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: CTG trials
Number of subjects: 104
Study: 32446494

Group type: EXPERIMENTAL
Intervention: Symptoms of anxiety
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Symptoms of depression
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Parental quality of life
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Impact on family
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Effect sizes
Number of subjects: 144
Study: 32446716

Group type: EXPERIMENTAL
Intervention: Non-selective beta-blockers (NSBBs)
Number of subjects: 38
Study: 32447411

Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Melanoma targeted radionuclide therapy (TRT)
Number of subjects: 0
Study: 32447421

Group type: EXPERIMENTAL
Intervention: PG-11047, 60-min intravenous infusions, doses ranging from 50 to 750 mg, administered on days 1, 8, and 15 of a 28-day cycle
Number of subjects: 46
Study: 32447545

Group type: EXPERIMENTAL
Intervention: Lasmiditan (200 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lasmiditan (100 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lasmiditan (50 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32447550

Group type: EXPERIMENTAL
Intervention: PD-H (visual hallucinations)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: PD-I (visual illusions)
Number of subjects: 82
Study: 32447743

Group type: EXPERIMENTAL
Intervention: Cladribine
Number of subjects: 2778

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2778

Group type: EXPERIMENTAL
Intervention: Cladribine (during 'at-risk' period)
Number of subjects: 2778

Group type: COMPARATOR
Intervention: Placebo (during 'at-risk' period)
Number of subjects: 2778

Group type: EXPERIMENTAL
Intervention: Partner pregnancies (female partners of cladribine-treated male patients)
Number of subjects: 2778
Study: 32448149

Group type: EXPERIMENTAL
Intervention: Cardiorespiratory fitness
Number of subjects: 1486

Group type: EXPERIMENTAL
Intervention: Muscular strength
Number of subjects: 1486

Group type: EXPERIMENTAL
Intervention: Body composition
Number of subjects: 1486
Study: 32448233

Group type: EXPERIMENTAL
Intervention: Gestational diabetes screening and management intervention
Number of subjects: 36
Study: 32448349

Group type: EXPERIMENTAL
Intervention: Fasting plasma glucose (FPG)
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Hemoglobin A1c (HbA1c)
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: 2-hour plasma glucose (2-h PG) after a 75-g oral glucose tolerance test
Number of subjects: 397
Study: 32448380

Group type: EXPERIMENTAL
Intervention: HLH-2004 criteria with a cutoff of 4 fulfilled criteria
Number of subjects: 2623

Group type: EXPERIMENTAL
Intervention: HScore with a cutoff of 168
Number of subjects: 2623

Group type: EXPERIMENTAL
Intervention: Adjusted HLH-2004 criteria cutoffs (hyperferritinemia to 3000 μg/L and fever to 38.2 °C)
Number of subjects: 2623

Group type: EXPERIMENTAL
Intervention: Higher number of fulfilled HLH-2004 criteria
Number of subjects: 2623

Group type: EXPERIMENTAL
Intervention: Higher HScore
Number of subjects: 2623

Group type: EXPERIMENTAL
Intervention: HScore cutoff of 168
Number of subjects: 2623
Study: 32448701

Group type: EXPERIMENTAL
Intervention: Vitamin D status (25-hydroxyvitamin D levels <20 ng/mL)
Number of subjects: 1191

Group type: EXPERIMENTAL
Intervention: Vitamin D status (25-hydroxyvitamin D levels at various thresholds)
Number of subjects: 1191

Group type: COMPARATOR
Intervention: 25-hydroxyvitamin D levels
Number of subjects: 1191
Study: 32448795

Group type: EXPERIMENTAL
Intervention: HPV testing with Pap
Number of subjects: 50000

Group type: EXPERIMENTAL
Intervention: Triage techniques (not specified)
Number of subjects: 50000
Study: 32448808

Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy
Number of subjects: 20
Study: 32448902

Group type: EXPERIMENTAL
Intervention: Raltegravir 12 mg/kg twice daily (administered after crushing)
Number of subjects: 0
Study: 32448949

Group type: EXPERIMENTAL
Intervention: Tisagenlecleucel
Number of subjects: 9
Study: 32449002

Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors (PPI)
Number of subjects: 542
Study: 32449053

Group type: EXPERIMENTAL
Intervention: Early intubation (before H8 following vasopressor onset)
Number of subjects: 859

Group type: EXPERIMENTAL
Intervention: Cumulative intubation during ICU stay
Number of subjects: 859

Group type: EXPERIMENTAL
Intervention: Multivariate analysis parameters associated with early intubation
Number of subjects: 859

Group type: EXPERIMENTAL
Intervention: Global R-square of the model
Number of subjects: 859

Group type: EXPERIMENTAL
Intervention: Neurological, respiratory and hemodynamic parameters
Number of subjects: 859

Group type: EXPERIMENTAL
Intervention: Center effect
Number of subjects: 859

Group type: EXPERIMENTAL
Intervention: Patient characteristics
Number of subjects: 859
Study: 32449068

Group type: EXPERIMENTAL
Intervention: Prone Position (PP) sessions
Number of subjects: 103
Study: 32449201

Group type: COMPARATOR
Intervention: Non-nutritive sweeteners (NNS)
Number of subjects: 979
Study: 32449223

Group type: EXPERIMENTAL
Intervention: High-risk lymph node ratio (LNR) > 7.6%
Number of subjects: 245

Group type: COMPARATOR
Intervention: Low-risk lymph node ratio (LNR) ≤ 7.6%
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: High-risk LNR
Number of subjects: 245
Study: 32449445

Group type: EXPERIMENTAL
Intervention: Subjects who could see clearly from 29 to 33 cm
Number of subjects: 500
Study: 32449505

Group type: EXPERIMENTAL
Intervention: Foot reflexology with conventional care
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional care without foot reflexology
Number of subjects: 80
Study: 32449684

Group type: EXPERIMENTAL
Intervention: Group Cognitive Behavioral Therapy (CBT) plus Treatment-As-Usual (TAU)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Group Exercise plus Treatment-As-Usual (TAU)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Wait-listing to receive Treatment-As-Usual (TAU) only
Number of subjects: 120
Study: 32449690

Group type: EXPERIMENTAL
Intervention: Mobile phone condition (Monsenso mDiary mobile app)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Pen-and-paper condition
Number of subjects: 80
Study: 32449927

Group type: EXPERIMENTAL
Intervention: Optimized criteria (PAC >20 ng/dL, PRC <2.5 μIU/mL, hypokalemia)
Number of subjects: 518

Group type: COMPARATOR
Intervention: Guideline criteria
Number of subjects: 518

Group type: COMPARATOR
Intervention: SIT or FST as confirmatory tests
Number of subjects: 518
Study: 32449975

Group type: EXPERIMENTAL
Intervention: Observational and Cross-Sectional Cohort Study of the Natural History and Phenotypic Spectrum of Farber Disease (NHS)
Number of subjects: 45
Study: 32450238

Group type: EXPERIMENTAL
Intervention: Gastroesophageal reflux (GER)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Acid GER
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Duodenogastroesophageal reflux (DGER)
Number of subjects: 131

Group type: COMPARATOR
Intervention: No reflux
Number of subjects: 131
Study: 32450725

Group type: EXPERIMENTAL
Intervention: Atezolizumab plus nab-paclitaxel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atezolizumab monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination studies with chemotherapy
Number of subjects: 0
Study: 32450820

Group type: EXPERIMENTAL
Intervention: Screening tool to identify high-risk individuals for prolonged sickness absence due to musculoskeletal disorders
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Health-related quality of life, health care utilization, and costs across different risk profiles
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Sickness absence data from NAV registry
Number of subjects: 600
Study: 32450847

Group type: EXPERIMENTAL
Intervention: Bronchoalveolar lavage fluid (BAL)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Tumour tissue
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Peritumoural tissue
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Lung microbiota analysis
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Lower lobe (LL) samples
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Lung tissues
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Microbiota composition
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Firmicutes in LL
Number of subjects: 18
Study: 32450874

Group type: EXPERIMENTAL
Intervention: COPE Program (Community Outreach and Patient Empowerment)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 173